Setting a new standard in achieving superior efficacy: ezetimibe + simvastatin.
Ezetimibe with simvastatin in combination inhibits both the absorption and production of cholesterol. This dual mechanism of inhibition substantially increases the capacity to decrease levels of atherogenic low-density lipoproteins, compared with that observed when either drug is used alone. Ezetimibe/simvastatin is more effective than atorvastatin or rosuvastatin monotherapy treatments in low-density lipoprotein cholesterol lowering and getting more patients to goals. Ezetimibe/simvastatin offers an important treatment alternative to patients who respond inadequately even to high-dose statin therapy.
Farnier
Michel
M
Point Médical, Rond Point de la Nation, 21000 Dijon, France. michelfarnier@nerim.net
D000924:Anticholesteremic Agents / Q000627:therapeutic use; D001384:Azetidines / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D000069438:Ezetimibe; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D019821:Simvastatin / Q000627:therapeutic use*; D016896:Treatment Outcome
D000924:Anticholesteremic Agents; D001384:Azetidines; D019821:Simvastatin; D000069438:Ezetimibe